lisinopril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 1587 76547-98-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lisinopril
  • linopril
  • nanopril
  • lisinopril hydrate
  • lisinopril dihydrate
  • anhydrous lisinopril
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
  • Molecular weight: 405.50
  • Formula: C21H31N3O5
  • CLOGP: -1.82
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -3.27
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 97 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 94 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.41 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.89 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 42 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1987 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 3426.31 28.54 745 5268 7651 2344421
Completed suicide 2548.15 28.54 703 5310 20331 2331741
Drug hypersensitivity 2432.37 28.54 813 5200 45830 2306242
Toxicity to various agents 1054.32 28.54 403 5610 32351 2319721
Acute kidney injury 1054.18 28.54 387 5626 27735 2324337
Swollen tongue 891.71 28.54 232 5781 5111 2346961
Cough 852.11 28.54 347 5666 32770 2319302
Hyperkalaemia 628.34 28.54 180 5833 5713 2346359
Hypotension 627.25 28.54 278 5735 32158 2319914
Intestinal angioedema 551.71 28.54 85 5928 51 2352021
Lip swelling 432.90 28.54 129 5884 4692 2347380
Dizziness 353.88 28.54 232 5781 58433 2293639
Dyspnoea 343.28 28.54 255 5758 78478 2273594
Swelling face 339.76 28.54 127 5886 9366 2342706
Hyponatraemia 328.22 28.54 136 5877 13189 2338883
Hypertension 301.33 28.54 160 5853 27201 2324871
Cardio-respiratory arrest 297.01 28.54 114 5899 9032 2343040
Blood pressure increased 271.53 28.54 128 5885 16858 2335214
Vomiting 252.82 28.54 205 5808 71397 2280675
Drug interaction 250.90 28.54 145 5868 29018 2323054
Cardiac arrest 209.64 28.54 103 5910 14827 2337245
Nausea 209.13 28.54 225 5788 111964 2240108
Confusional state 203.80 28.54 119 5894 24225 2327847
Syncope 191.98 28.54 101 5912 16774 2335298
Renal failure 183.72 28.54 99 5914 17250 2334822
Diarrhoea 177.57 28.54 180 5833 83384 2268688
Respiratory arrest 168.71 28.54 68 5945 6110 2345962
Dysphagia 163.90 28.54 83 5930 12722 2339350
Abdominal pain 150.29 28.54 112 5901 34262 2317810
Poisoning 147.22 28.54 50 5963 2770 2349302
Dehydration 145.48 28.54 93 5920 22202 2329870
Intentional product misuse 140.68 28.54 68 5945 9421 2342651
Fatigue 139.96 28.54 160 5853 84713 2267359
Headache 126.82 28.54 148 5865 80031 2272041
Asthenia 125.60 28.54 115 5898 46811 2305261
Product complaint 124.03 28.54 50 5963 4488 2347584
Death 116.68 28.54 143 5870 81325 2270747
Product substitution issue 115.35 28.54 49 5964 5020 2347052
Pharyngeal oedema 114.84 28.54 44 5969 3449 2348623
Bradycardia 114.11 28.54 60 5953 9921 2342151
Blood creatinine increased 113.88 28.54 61 5952 10472 2341600
Blood pressure inadequately controlled 111.52 28.54 31 5982 869 2351203
Fall 108.02 28.54 106 5907 46993 2305079
Hypersensitivity 107.76 28.54 79 5934 23514 2328558
Lactic acidosis 106.48 28.54 47 5966 5283 2346789
Hypotensive transfusion reaction 104.32 28.54 15 5998 0 2352072
Respiratory distress 101.73 28.54 45 5968 5084 2346988
Inappropriate antidiuretic hormone secretion 97.64 28.54 35 5978 2274 2349798
Malaise 96.83 28.54 108 5905 55477 2296595
Rash 95.75 28.54 111 5902 59447 2292625
Obstructive airways disorder 94.44 28.54 30 5983 1343 2350729
Blood pressure decreased 92.89 28.54 51 5962 9185 2342887
Urticaria 92.60 28.54 73 5940 24188 2327884
Oligohydramnios 91.71 28.54 27 5986 933 2351139
Metabolic acidosis 88.90 28.54 43 5970 5955 2346117
Osteoarthritis 88.71 28.54 45 5968 6901 2345171
Blood potassium increased 84.32 28.54 31 5982 2165 2349907
Hypokalaemia 80.90 28.54 49 5964 10605 2341467
Myoclonus 80.61 28.54 31 5982 2452 2349620
Respiratory failure 79.72 28.54 53 5960 13475 2338597
Medication error 79.11 28.54 40 5973 6091 2345981
Throat tightness 78.66 28.54 36 5977 4400 2347672
Overdose 78.31 28.54 61 5952 19846 2332226
Speech disorder 77.11 28.54 40 5973 6424 2345648
Pancreatitis acute 77.02 28.54 34 5979 3819 2348253
Pruritus 76.75 28.54 85 5928 43255 2308817
Drug ineffective 75.69 28.54 131 5882 101493 2250579
Wheezing 74.70 28.54 39 5974 6345 2345727
Drug dispensed to wrong patient 73.71 28.54 13 6000 34 2352038
Swelling 70.67 28.54 53 5960 16297 2335775
Type 2 diabetes mellitus 69.82 28.54 27 5986 2167 2349905
Atrial fibrillation 69.43 28.54 49 5964 13719 2338353
Hypovolaemia 69.37 28.54 23 5990 1180 2350892
Labile blood pressure 69.19 28.54 16 5997 207 2351865
Stridor 69.07 28.54 20 5993 651 2351421
Tongue oedema 68.63 28.54 21 5992 829 2351243
Loss of consciousness 68.42 28.54 55 5958 18712 2333360
Mental status changes 67.89 28.54 35 5978 5547 2346525
Chest pain 67.51 28.54 65 5948 28072 2324000
Hypoxia 67.08 28.54 36 5977 6191 2345881
Renal tubular necrosis 66.84 28.54 24 5989 1566 2350506
Tenderness 66.05 28.54 25 5988 1893 2350179
Exposure via ingestion 65.90 28.54 20 5993 768 2351304
Somnolence 65.49 28.54 59 5954 23426 2328646
Renal impairment 65.46 28.54 42 5971 10050 2342022
Ascites 61.97 28.54 33 5980 5587 2346485
Spinal stenosis 61.85 28.54 22 5991 1396 2350676
Gastrooesophageal reflux disease 61.85 28.54 39 5974 9056 2343016
Anxiety 61.51 28.54 63 5950 29296 2322776
Thermohypoaesthesia 61.22 28.54 10 6003 13 2352059
Oedema peripheral 61.00 28.54 57 5956 23706 2328366
Pancreatitis 60.91 28.54 37 5976 8042 2344030
Condition aggravated 60.53 28.54 65 5948 31914 2320158
Joint swelling 58.57 28.54 48 5965 16771 2335301
Foetal methotrexate syndrome 57.41 28.54 9 6004 7 2352065
Haemodialysis 57.20 28.54 23 5990 2046 2350026
Anaphylactic reaction 57.10 28.54 38 5975 9667 2342405
Hypoglycaemia 57.04 28.54 36 5977 8371 2343701
Lymphomatoid papulosis 56.97 28.54 11 6002 54 2352018
Multimorbidity 56.68 28.54 12 6001 100 2351972
Laryngeal oedema 56.24 28.54 20 5993 1268 2350804
Dysarthria 55.73 28.54 32 5981 6270 2345802
Nodular rash 55.70 28.54 11 6002 62 2352010
Tachycardia 55.40 28.54 46 5967 16363 2335709
Weight decreased 54.27 28.54 58 5955 28313 2323759
Palpitations 53.22 28.54 45 5968 16411 2335661
Orthostatic hypotension 53.04 28.54 24 5989 2855 2349217
Abdominal tenderness 52.41 28.54 18 5995 1029 2351043
Fear of eating 52.38 28.54 9 6004 19 2352053
Sight disability 52.06 28.54 9 6004 20 2352052
Accidental overdose 51.47 28.54 26 5987 3946 2348126
Acute myocardial infarction 51.03 28.54 28 5985 5027 2347045
Abdominal pain upper 51.01 28.54 50 5963 22050 2330022
Haematemesis 50.80 28.54 26 5987 4056 2348016
Extensor plantar response 49.88 28.54 13 6000 283 2351789
Hypertensive crisis 49.65 28.54 22 5991 2491 2349581
Intentional overdose 49.56 28.54 37 5976 11284 2340788
Vision blurred 49.27 28.54 41 5972 14627 2337445
Ventricular fibrillation 49.13 28.54 21 5992 2180 2349892
Oedema mouth 48.90 28.54 16 5997 787 2351285
Acute hepatic failure 48.59 28.54 22 5991 2620 2349452
Grip strength decreased 48.39 28.54 17 5996 1040 2351032
Abdominal distension 47.76 28.54 35 5978 10376 2341696
Facial nerve disorder 47.38 28.54 10 6003 82 2351990
Circulatory collapse 47.18 28.54 24 5989 3696 2348376
Cerebral thrombosis 46.32 28.54 13 6000 377 2351695
Anaemia 46.25 28.54 59 5954 34733 2317339
Dry mouth 45.40 28.54 31 5982 8222 2343850
Chest discomfort 45.33 28.54 39 5974 14556 2337516
Adverse drug reaction 45.30 28.54 31 5982 8252 2343820
Blood pressure systolic increased 44.68 28.54 20 5993 2319 2349753
Urinary retention 44.60 28.54 23 5990 3644 2348428
Oliguria 44.24 28.54 17 5996 1340 2350732
Oedema 43.89 28.54 33 5980 10170 2341902
Pain 43.63 28.54 78 5935 61779 2290293
Therapeutic response unexpected 43.49 28.54 23 5990 3836 2348236
Hyperreflexia 43.20 28.54 15 5998 886 2351186
Amaurosis 43.06 28.54 10 6003 132 2351940
Shock 42.70 28.54 23 5990 3981 2348091
Left ventricular hypertrophy 42.62 28.54 14 5999 697 2351375
Blood sodium decreased 42.25 28.54 21 5992 3079 2348993
Hyperventilation 42.24 28.54 16 5997 1213 2350859
Choking 42.18 28.54 17 5996 1521 2350551
Myocardial infarction 41.98 28.54 42 5971 18971 2333101
Dyspepsia 40.49 28.54 31 5982 9813 2342259
Face oedema 40.21 28.54 22 5991 3926 2348146
Optic ischaemic neuropathy 40.09 28.54 11 6002 293 2351779
Blindness cortical 39.93 28.54 9 6004 103 2351969
Hypothermia 39.86 28.54 18 5995 2130 2349942
Treatment failure 39.36 28.54 27 5986 7212 2344860
Abdominal discomfort 39.34 28.54 39 5974 17417 2334655
Drug intolerance 39.27 28.54 35 5978 13682 2338390
Blood urea increased 39.26 28.54 21 5992 3584 2348488
Hyperlipidaemia 39.08 28.54 19 5994 2655 2349417
Unresponsive to stimuli 38.47 28.54 23 5990 4853 2347219
Neuromyelitis optica spectrum disorder 38.44 28.54 10 6003 216 2351856
Electrocardiogram T wave peaked 38.42 28.54 8 6005 61 2352011
Presyncope 38.20 28.54 21 5992 3782 2348290
Gastrointestinal haemorrhage 38.14 28.54 33 5980 12402 2339670
Proteinuria 37.93 28.54 19 5994 2831 2349241
Hallucination, visual 37.14 28.54 19 5994 2960 2349112
Delirium 37.01 28.54 23 5990 5200 2346872
Sinus bradycardia 36.96 28.54 17 5996 2099 2349973
Paraesthesia 36.76 28.54 42 5971 22046 2330026
Drug clearance decreased 36.41 28.54 9 6004 157 2351915
Gait disturbance 36.06 28.54 42 5971 22503 2329569
Pupillary reflex impaired 35.61 28.54 11 6002 448 2351624
Decreased appetite 35.27 28.54 47 5966 28844 2323228
Agitation 35.26 28.54 30 5983 11021 2341051
Muscular weakness 34.90 28.54 34 5979 14863 2337209
Lethargy 34.82 28.54 27 5986 8703 2343369
Laryngospasm 34.65 28.54 12 6001 703 2351369
Restlessness 34.64 28.54 21 5992 4542 2347530
Pyrexia 34.41 28.54 65 5948 53643 2298429
Cardiac murmur 34.38 28.54 15 5998 1636 2350436
Loss of personal independence in daily activities 34.17 28.54 22 5991 5289 2346783
Peripheral swelling 33.66 28.54 36 5977 17561 2334511
Myalgia 33.26 28.54 41 5972 23292 2328780
Purpura senile 33.17 28.54 6 6007 19 2352053
Rotator cuff repair 33.01 28.54 9 6004 234 2351838
Gastrointestinal disorder 32.18 28.54 26 5987 8891 2343181
Glomerulonephritis membranous 32.02 28.54 8 6005 146 2351926
Foetal exposure during pregnancy 31.93 28.54 21 5992 5231 2346841
Hypophagia 31.90 28.54 19 5994 3981 2348091
Rhabdomyolysis 31.79 28.54 23 5990 6681 2345391
Eosinophilic pneumonia 31.54 28.54 10 6003 444 2351628
Contusion 31.45 28.54 30 5983 12780 2339292
Bundle branch block left 30.91 28.54 12 6001 972 2351100
Chronic obstructive pulmonary disease 30.67 28.54 23 5990 7054 2345018
Blood glucose increased 30.58 28.54 29 5984 12261 2339811
Tremor 30.57 28.54 37 5976 20624 2331448
Dialysis 30.48 28.54 15 5998 2152 2349920
Salivary gland enlargement 30.45 28.54 7 6006 88 2351984
Dyspnoea exertional 30.30 28.54 21 5992 5699 2346373
Feeling abnormal 29.76 28.54 39 5974 23542 2328530
Hypoaldosteronism 29.52 28.54 6 6007 40 2352032
Hypovolaemic shock 29.43 28.54 11 6002 803 2351269
Cardiac failure congestive 29.15 28.54 32 5981 16069 2336003
Nodal rhythm 28.98 28.54 9 6004 373 2351699
Macroglossia 28.83 28.54 7 6006 113 2351959

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 18099.98 38.20 3529 6543 6135 1730574
Hyperkalaemia 2726.40 38.20 764 9308 7783 1728926
Completed suicide 2499.31 38.20 829 9243 15483 1721226
Acute kidney injury 2307.15 38.20 955 9117 33989 1702720
Hypotension 1489.67 38.20 671 9401 28983 1707726
Swollen tongue 1202.19 38.20 318 9754 2490 1734219
Lip swelling 1042.65 38.20 284 9788 2511 1734198
Cough 932.86 38.20 426 9646 18771 1717938
Drug hypersensitivity 873.08 38.20 379 9693 14756 1721953
Toxicity to various agents 808.64 38.20 442 9630 28699 1708010
Swelling face 664.88 38.20 224 9848 4259 1732450
Wheezing 558.86 38.20 193 9879 3960 1732749
Dyspnoea 470.57 38.20 394 9678 51665 1685044
Anaphylactic reaction 427.45 38.20 176 9896 5937 1730772
Syncope 421.97 38.20 226 9846 13943 1722766
Dizziness 406.21 38.20 305 9767 34056 1702653
Dysphagia 403.79 38.20 197 9875 9971 1726738
Bradycardia 347.39 38.20 180 9892 10354 1726355
Blood creatinine increased 345.16 38.20 197 9875 13749 1722960
Dehydration 319.54 38.20 204 9868 17454 1719255
Intentional overdose 284.58 38.20 142 9930 7528 1729181
Blood potassium increased 269.59 38.20 99 9973 2431 1734278
Pharyngeal oedema 266.10 38.20 88 9984 1565 1735144
Blood urea increased 247.82 38.20 111 9961 4600 1732109
Orthostatic hypotension 240.30 38.20 99 9973 3332 1733377
Hypovolaemia 195.49 38.20 65 10007 1175 1735534
Metabolic acidosis 194.32 38.20 98 9974 5304 1731405
Shock 190.38 38.20 89 9983 4072 1732637
Lactic acidosis 184.34 38.20 93 9979 5036 1731673
Drug interaction 180.82 38.20 176 9896 27782 1708927
Cardiac arrest 177.69 38.20 137 9935 15793 1720916
Hypertension 176.07 38.20 148 9924 19300 1717409
Urticaria 174.28 38.20 122 9950 12119 1724590
Respiratory arrest 172.97 38.20 93 9979 5746 1730963
Renal failure 170.31 38.20 147 9925 19870 1716839
Rash 164.49 38.20 195 9877 38498 1698211
Hyponatraemia 162.49 38.20 104 9968 8896 1727813
Overdose 161.33 38.20 132 9940 16569 1720140
Renal tubular necrosis 154.63 38.20 63 10009 2056 1734653
Dysphonia 153.26 38.20 73 9999 3482 1733227
Asthenia 146.07 38.20 174 9898 34496 1702213
Cardio-respiratory arrest 142.52 38.20 97 9975 9196 1727513
Pancreatitis 137.06 38.20 86 9986 7101 1729608
Fall 135.55 38.20 149 9923 27065 1709644
Vomiting 130.62 38.20 173 9899 38142 1698567
Pruritus 129.46 38.20 135 9937 23087 1713622
Blood pressure increased 125.33 38.20 95 9977 10658 1726051
Speech disorder 119.64 38.20 67 10005 4481 1732228
Pancreatitis acute 117.93 38.20 64 10008 4023 1732686
Swelling 114.36 38.20 76 9996 6920 1729789
Suicide attempt 113.04 38.20 77 9995 7304 1729405
Nausea 111.02 38.20 187 9885 51009 1685700
Laryngeal oedema 110.14 38.20 39 10033 857 1735852
Diarrhoea 107.99 38.20 190 9882 53662 1683047
Renal impairment 107.77 38.20 92 9980 12222 1724487
Hypophagia 107.16 38.20 57 10015 3440 1733269
Electrocardiogram T wave peaked 105.81 38.20 25 10047 113 1736596
Hypersensitivity 99.59 38.20 82 9990 10362 1726347
Poisoning 97.07 38.20 48 10024 2484 1734225
Respiratory distress 96.50 38.20 61 10011 5096 1731613
Intestinal angioedema 95.61 38.20 19 10053 28 1736681
Stridor 92.38 38.20 30 10042 501 1736208
Pulmonary oedema 92.13 38.20 65 10007 6521 1730188
Drooling 91.99 38.20 33 10039 754 1735955
Respiratory failure 85.56 38.20 87 9985 14418 1722291
Obstructive airways disorder 85.47 38.20 34 10038 1040 1735669
Hypoglycaemia 81.99 38.20 67 10005 8371 1728338
Throat tightness 81.77 38.20 37 10035 1565 1735144
Confusional state 76.87 38.20 99 9973 21179 1715530
Chest pain 75.64 38.20 95 9977 19819 1716890
Oral allergy syndrome 75.31 38.20 13 10059 2 1736707
Loss of consciousness 74.87 38.20 82 9990 14793 1721916
Product substitution issue 74.61 38.20 44 10028 3242 1733467
Oropharyngeal pain 73.11 38.20 50 10022 4768 1731941
Hypotensive transfusion reaction 72.94 38.20 13 10059 5 1736704
Tongue oedema 72.71 38.20 26 10046 588 1736121
Hypoxia 72.34 38.20 54 10018 5909 1730800
Oedema peripheral 70.19 38.20 81 9991 15469 1721240
Mental status changes 69.24 38.20 53 10019 6022 1730687
Fatigue 68.66 38.20 152 9920 50629 1686080
Oropharyngeal swelling 67.11 38.20 18 10054 147 1736562
Renal tubular acidosis 66.93 38.20 21 10051 312 1736397
Presyncope 66.21 38.20 38 10034 2660 1734049
Intentional product misuse 64.38 38.20 55 10017 7303 1729406
Treatment noncompliance 62.86 38.20 47 10025 5154 1731555
Dysarthria 62.40 38.20 47 10025 5212 1731497
Lip oedema 61.61 38.20 23 10049 590 1736119
Cardiogenic shock 58.72 38.20 34 10038 2420 1734289
Blood pressure decreased 58.57 38.20 53 10019 7593 1729116
Hypokalaemia 58.54 38.20 49 10023 6325 1730384
Odynophagia 56.89 38.20 23 10049 734 1735975
Electrocardiogram QRS complex prolonged 56.37 38.20 23 10049 752 1735957
Oedema 54.87 38.20 49 10023 6899 1729810
Electrocardiogram change 53.60 38.20 16 10056 199 1736510
Nodular rash 53.23 38.20 11 10061 22 1736687
Agitation 50.68 38.20 58 10014 10968 1725741
Product complaint 50.46 38.20 31 10041 2459 1734250
Medication error 48.88 38.20 39 10033 4704 1732005
Blood creatine increased 46.59 38.20 20 10052 744 1735965
Haemodialysis 46.57 38.20 30 10042 2586 1734123
Hypovolaemic shock 46.42 38.20 21 10051 887 1735822
Oedema mouth 44.77 38.20 16 10056 361 1736348
Face oedema 44.60 38.20 28 10044 2308 1734401
Tachycardia 44.37 38.20 58 10014 12570 1724139
Acute myocardial infarction 44.32 38.20 48 10024 8539 1728170
Rhabdomyolysis 43.81 38.20 54 10018 11036 1725673
Lymphomatoid papulosis 42.87 38.20 11 10061 74 1736635
Dialysis 41.39 38.20 27 10045 2377 1734332
Mouth swelling 41.18 38.20 14 10058 271 1736438
Blood pressure inadequately controlled 40.55 38.20 17 10055 596 1736113
Contraindicated product administered 39.93 38.20 22 10050 1422 1735287
Acidosis 39.19 38.20 22 10050 1475 1735234
Muscular weakness 39.03 38.20 49 10023 10200 1726509
Paraesthesia 38.27 38.20 49 10023 10402 1726307

Pharmacologic Action:

SourceCodeDescription
ATC C09AA03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
ATC C10BX07 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35674 antihypertensive agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Myocardial infarction indication 22298006 DOID:5844
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Superficial Ocular Infection indication
Diabetic retinopathy off-label use 4855003 DOID:8947
Atrial fibrillation off-label use 49436004 DOID:0060224
Blepharoconjunctivitis off-label use 68659002 DOID:2456
Dacryocystitis off-label use 85777005 DOID:9938
Corneal ulcer off-label use 91514001 DOID:8463
Diabetic renal disease off-label use 127013003
Bacterial conjunctivitis off-label use 128350005 DOID:9700
Acute scleroderma renal crisis off-label use 236503001
Meibomianitis off-label use 309779001
Infective blepharitis off-label use 312219000
Bacterial keratitis off-label use 314557000
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Migraine Prevention off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Aortic valve stenosis contraindication 60573004 DOID:1712
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Acute hepatic failure contraindication 197270009
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Disorder of electrolytes contraindication 237840007
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Hemodialysis with High-Flux Membrane contraindication
Intestinal Angioedema contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.18 acidic
pKa2 3.18 acidic
pKa3 11.0 Basic
pKa4 6.95 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 METHOD OF TREATING HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 TREATMENT OF HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10039800 Nov. 6, 2035 TREATMENT OF MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 METHOD OF TREATING HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 TREATMENT OF HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 10406199 Nov. 6, 2035 TREATMENT OF MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 METHOD OF TREATING HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 TREATMENT OF HEART FAILURE
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 TREATMENT OF HYPERTENSION
1MG/ML QBRELIS SILVERGATE PHARMS N208401 July 29, 2016 RX SOLUTION ORAL 9616096 Nov. 6, 2035 TREATMENT OF MYOCARDIAL INFARCTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.92 WOMBAT-PK CHEMBL
Angiotensin-converting enzyme Enzyme Ki 7.29 CHEMBL

External reference:

IDSource
4019380 VUID
N0000147537 NUI
C0065374 UMLSCUI
D00362 KEGG_DRUG
108575001 SNOMEDCT_US
4019380 VANDF
000658 NDDF
44066 MMSL
29046 RXNORM
386873009 SNOMEDCT_US
4985 MMSL
d00732 MMSL
CHEMBL419213 ChEMBL_ID
CHEMBL1237 ChEMBL_ID
DB00722 DRUGBANK_ID
E7199S1YWR UNII
83915-83-7 SECONDARY_CAS_RN
LPR PDB_CHEM_ID
CHEBI:6503 CHEBI
D017706 MESH_DESCRIPTOR_UI
CHEMBL1729579 ChEMBL_ID
5362119 PUBCHEM_CID
6360 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PRINIVIL HUMAN PRESCRIPTION DRUG LABEL 1 0006-0019 TABLET 5 mg ORAL NDA 18 sections
PRINIVIL HUMAN PRESCRIPTION DRUG LABEL 1 0006-0106 TABLET 10 mg ORAL NDA 18 sections
PRINIVIL HUMAN PRESCRIPTION DRUG LABEL 1 0006-0207 TABLET 20 mg ORAL NDA 18 sections
Lisinopril with Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0143-1262 TABLET 10 mg ORAL ANDA 12 sections
Lisinopril with Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0143-1263 TABLET 20 mg ORAL ANDA 12 sections
Lisinopril with Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0143-1264 TABLET 20 mg ORAL ANDA 12 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1266 TABLET 5 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1267 TABLET 10 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1268 TABLET 20 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1270 TABLET 40 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-9713 TABLET 20 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-9714 TABLET 10 mg ORAL ANDA 17 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-9715 TABLET 5 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0025 TABLET 2.50 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0101 TABLET 10 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0102 TABLET 20 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0103 TABLET 30 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0104 TABLET 40 mg ORAL ANDA 17 sections
Lisinopril and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0152 TABLET 20 mg ORAL ANDA 13 sections
Lisinopril and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0173 TABLET 20 mg ORAL ANDA 13 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0602 TABLET 2.50 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0605 TABLET 5 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0610 TABLET 10 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0620 TABLET 20 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0630 TABLET 30 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-0640 TABLET 40 mg ORAL ANDA 17 sections
lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0185-5400 TABLET 5 mg ORAL ANDA 17 sections
Lisinopril and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-7100 TABLET 10 mg ORAL ANDA 13 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0440-7674 TABLET 5 mg ORAL ANDA 13 sections
Lisinopril HUMAN PRESCRIPTION DRUG LABEL 1 0591-0405 TABLET 2.50 mg ORAL ANDA 17 sections